Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Novartis AG ADS (NY: NVS)
74.36 USD  +0.54 (+0.73%)
Official Closing Price  /  Updated: 6:40 PM EDT, May 24, 2013  /  Add to My Watchlist      
View: Quote News Research
Blog posts about Novartis AG ADS
 
< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
(EU) Emerging Markets: The Way Forward
December 07, 2011
According to Irish orator, philosopher, & politician Edmund Burke, change is the most powerful... Visit StockBlogHub to view complete post. Read More
category Mylan Inc/ , Glaxosmithkline plc , Sanofi/Aventis , and 23 more.
from Stock Blog Hub
Emerging Markets: The Way Forward
December 07, 2011
According to Irish orator, philosopher, & politician Edmund Burke, change is the most powerful law of nature. The winds of change seem to be sweeping across the pharmaceutical industry as well. Until... Read More
category AZN , FRX , External Research , and 10 more.
from DailyMarkets.com
Regeneron’s Eylea Data Unimpressive
December 07, 2011
Recently, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and partner Bayer (BAYRY) presented not very encouraging two-year data from a couple of parallel late-stage studies (VIEW 1 and VIEW 2) of their... Read More
category NVS , REGN , Stocks , and 3 more.
from DailyMarkets.com
(MYL) Mylan Earns FDA Approval
December 05, 2011
Generic maker, Mylan Inc. (MYL) recently announced that its Indian subsidiary Mylan Laboratories... Visit StockBlogHub to view complete post. Read More
category Mylan Inc/ , TEVA , ABT , and 15 more.
from Stock Blog Hub
Good News For Mylan
December 05, 2011
Generic maker, Mylan Inc. (NYSE:MYL) recently announced that its Indian subsidiary Mylan Laboratories has received tentative approval from the US Food & Drug Administration (FDA) for a fixed-dose... Read More
category TEVA , External Research , Contributor , and 8 more.
from DailyMarkets.com
(ALNY) Alnylam Pharmaceuticals Completes Trial Enrollment
December 02, 2011
Alnylam Pharmaceuticals Inc. (ALNY) recently announced it has completed enrollment in a mid-stage... Visit StockBlogHub to view complete post. Read More
category Biotechnology , MDT , Cubist Pharmaceuticals Inc/ , and 11 more.
from Stock Blog Hub
Alnylam Completes Trial Enrollment
December 01, 2011
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) recently announced it has completed enrollment in a mid-stage study of its pipeline candidate ALN-RSV01, an RNA interference technology (RNAi) therapeutic... Read More
category RHHBY , MDT , External Research , and 7 more.
from DailyMarkets.com
(MYL) Mylan Approved for Zinecard Generic
December 01, 2011
Mylan, Inc.’s (MYL) generic business was boosted further with the approval from the U.S. Food and... Visit StockBlogHub to view complete post. Read More
category Watson Pharmaceuticals Inc/ , Mylan Inc/ , TEVA , and 7 more.
from Stock Blog Hub
Mylan Approved For Zinecard Generic
November 30, 2011
Mylan, Inc.’s (NYSE:MYL) generic business was boosted further with the approval from the U.S. Food and Drug Administration (FDA) for its generic version of Pharmacia & Upjohn’s Zinecard injection.... Read More
category NVS , TEVA , WPI , and 4 more.
from DailyMarkets.com
(NVS) Novartis’ Rasitrio Cleared in European Union
November 28, 2011
Novartis (NVS) recently announced that its triple combination hypertension pill Rasitrio has been... Visit StockBlogHub to view complete post. Read More
category NVS , Healthcare , Drug Manufacturers / Major , and 1 more.
from Stock Blog Hub
Novartis’ Rasitrio Cleared In EU
November 28, 2011
Novartis (NYSE:NVS) recently announced that its triple combination hypertension pill Rasitrio has been cleared in the European Union (EU). Rasitrio combines the currently marketed hypertension pill... Read More
category NVS , Stocks , External Research , and 1 more.
from DailyMarkets.com
(MYL) Mylan Settles with Novartis
November 28, 2011
Mylan, Inc. (MYL) recently announced a settlement agreement with Novartis (NVS) relating to the... Visit StockBlogHub to view complete post. Read More
category Watson Pharmaceuticals Inc/ , Mylan Inc/ , Glaxosmithkline plc , and 11 more.
from Stock Blog Hub
(ALNY) Alnylam Pharmaceuticals Reveals ALNTTR01 Trial Data
November 28, 2011
Alnylam Pharmaceuticals Inc. (ALNY) recently presented data from an early stage study of its... Visit StockBlogHub to view complete post. Read More
category Biotechnology , MDT , Cubist Pharmaceuticals Inc/ , and 11 more.
from Stock Blog Hub
Novartis @ Year Lows
November 25, 2011
New York, November 25th (TradersHuddle.com) - Shares of Novartis AG ( NYSE:NVS ) booked a new 52 week low by trading below $52.09, traders are definitely monitoring Novartis' price action to see if... Read More
from TradersHuddle.com
Alnylam Reveals ALNTTR01 Trial Data
November 25, 2011
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) recently presented data from an early stage study of its pipeline candidate ALN-TTR01 at a scientific conference in Japan. ALN-TTR01 is a systemically... Read More
category RHHBY , MDT , External Research , and 7 more.
from DailyMarkets.com
Mylan Settles With Novartis
November 23, 2011
Mylan, Inc. (NYSE:MYL) recently announced a settlement agreement with Novartis (NYSE:NVS) relating to the generic version of Novartis’ bioidentical estrogen therapy Vivelle-Dot. As a result of the... Read More
category NVS , TEVA , WPI , and 6 more.
from DailyMarkets.com
Regeneron Drug Cleared In The US
November 21, 2011
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) recently received a huge boost when the US Food and Drug Administration (FDA) cleared its injectable eye drug Eylea (aflibercept) for treating patients... Read More
category NVS , REGN , Stocks , and 3 more.
from DailyMarkets.com
Cooper Expands Avaira Recall
November 17, 2011
CooperVision, a unit of The Cooper Companies (NYSE:COO), recently reported that it was widening the scope of its global recall of the Avaira brand of contact lenses to include select lots of Avaira... Read More
category NVS , jnj , COO , and 3 more.
from DailyMarkets.com
Incyte Drug Cleared In The US
November 17, 2011
Incyte Corporation (NASDAQ:INCY) recently received a huge boost when the US Food and Drug Administration (FDA) approved its cancer drug Jakafi (ruxolitinib), an oral janus-associated kinase (JAK) 1 and... Read More
category NVS , INCY , Stocks , and 2 more.
from DailyMarkets.com
Reaffirming Gen-Probe At Neutral
November 10, 2011
We retain our Neutral recommendation on diagnostic products maker Gen-Probe (NASDAQ:GPRO) following its mixed third quarter results. Its adjusted earnings of 57 cents a share for the quarter topped the... Read More
category RHHBY , External Research , Contributor , and 5 more.
from DailyMarkets.com
Novartis’ ACZ885 Meets Study Goal
November 09, 2011
Novartis (NYSE:NVS) recently announced that a late-stage trial evaluating its pipeline candidate, ACZ885, for the treatment of children with active systemic juvenile idiopathic arthritis (SJIA) met the... Read More
category NVS , Stocks , External Research , and 1 more.
from DailyMarkets.com
Up/Downgrades (CBL, CHSP, DX, EMR, HON, KRC, MFA, RAX, TMH, ATK, BKE, CBE, EXPE, ITW, NVS, PXD, SNY, STJ, WMS)
November 08, 2011
New York, November 8th (TradersHuddle.com) – Following are some of the top upgrades and downgrades before the market open. Upgrades CBL & Associates Propertie. Read More -- Read More
from TradersHuddle.com
Mixed Bag From Gen-Probe
November 03, 2011
Diagnostic products maker Gen-Probe’s (NASDAQ:GPRO) third-quarter fiscal 2011 adjusted (excluding one-time charges) earnings of 57 cents trounced the Zacks Consensus Estimate by 3 cents while matching... Read More
category RHHBY , External Research , Contributor , and 5 more.
from DailyMarkets.com
Human Genome Downgraded
November 02, 2011
We are downgrading Human Genome Sciences Inc. (NASDAQ:HGSI) to Underperform from Neutral following the disappointing third quarter 2011 results reported by the company. Our target price is $10.00. The... Read More
category NVS , Stocks , HGSI , and 3 more.
from DailyMarkets.com
Loss Widens At Incyte
November 02, 2011
Incyte Corporation’s (NASDAQ:INCY) third quarter 2011 loss of $0.42 per share was wider than the year-ago loss by $0.16. The wider year-over-year loss was attributable to higher operating expenses and... Read More
category NVS , INCY , Stocks , and 4 more.
from DailyMarkets.com
Alnylam Loss Tapers, Inks GSK Deal
November 02, 2011
Alnylam Pharmaceuticals Inc.’s (NASDAQ:ALNY) third quarter 2011 loss of 31 cents per share was narrower than the Zacks Consensus Estimate of a loss of 36 cents per share. Lower operating expenses led... Read More
category RHHBY , External Research , Contributor , and 5 more.
from DailyMarkets.com
Up/Downgrades (AGP, ABFS, BRCM, JNPR, LAMR, MMC, NBR, OCR, RES, UQM, WY, ANN, ACI, CNI, CVX, FOSL, NVS, OLN, SNDK)
October 31, 2011
New York, October 31st (TradersHuddle.com) – Following are some of the top upgrades and downgrades before the market open. Upgrades Amerigroup (<a href="http://ww. Read More -- Read More
from TradersHuddle.com
Biogen Impresses, Beats On All Fronts
October 28, 2011
Biogen Idec (NASDAQ:BIIB) reported third-quarter earnings per share of $1.59, well above the Zacks Consensus Estimate of $1.51 and the year-ago earnings of $1.33. Excluding the impact of stock-based... Read More
category NVS , RHHBY , ELN , and 4 more.
from DailyMarkets.com
Bristol-Myers Tops, Adjusts View
October 27, 2011
Bristol-Myers Squibb Company’s (NYSE:BMY) third quarter 2011 earnings (excluding special items) of $0.61 per share surpassed the Zacks Consensus Estimate by $0.03 and the year-ago earnings by $0.02.... Read More
category AZN , External Research , Contributor , and 5 more.
from DailyMarkets.com
Weak Benlysta Sales Hurt Human Genome
October 27, 2011
Human Genome Sciences Inc.’s (NASDAQ:HGSI) third quarter 2011 loss of $0.45 per share was wider than the Zacks Consensus loss estimate by $0.06 and the year-ago loss by $0.23. The wider loss incurred... Read More
category NVS , Stocks , HGSI , and 3 more.
from DailyMarkets.com
< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here